Antisense therapies for movement disorders

Abstract

Currently, few disease‐modifying therapies exist for degenerative movement disorders. Antisense oligonucleotides are small DNA oligonucleotides, usually encompassing ∼20 base pairs, that can potentially target any messenger RNA of interest. Antisense oligonucleotides often contain modifications to the phosphate backbone, the sugar moiety, and the nucleotide base. The development of antisense oligonucleotide therapies spinal muscular atrophy and Duchenne muscular dystrophy suggest potentially wide‐ranging therapeutic applications for antisense oligonucleotides in neurology. Successes with these two diseases have heightened interest in academia and the pharmaceutical industry to develop antisense oligonucleotides for several movement disorders, including, spinocerebellar ataxias, Huntington's disease, and Parkinson's disease. Compared to small molecules, antisense oligonucleotide–based therapies have an advantage because the target disease gene sequence is the immediate path to identifying the therapeutically effective complementary antisense oligonucleotide. In this review we describe the different types of antisense oligonucleotide chemistries and their potential use for the treatment of human movement disorders. © 2019 International Parkinson and Movement Disorder Society

A Synonymous Variant c.579A>G in the ETFDH Gene Caused Exon Skipping in a Patient With Late-Onset Multiple Acyl-CoA Dehydrogenase Deficiency: A Case Report

“…ASOs are short synthetic oligonucleotides that can bind to pre-RNA through Watson-Crick base pairing and modulate pre-RNA splicing in the target gene bypassing the disease-causing mutation. Currently, several ASOs have received approval by the U.S. Food and Drug Administration for the therapy of neurological disorders (15). Our patient may also benefit from ASO-based therapy in the future who carry an ETFDH synonymous variant causing exon skipping.…”

Towards ecologically valid biomarkers: real-life gait assessment in cerebellar ataxia

“…It has been shown in laboratory-based assessments that measures of spatial and temporal movement variability allow distinctively to capture and characterize the specificities of ataxic gait [3][4][5][6][7][8][9][10] . Moreover, they allow to quantify disease severity even at preclinical stages of DCA 11,12 and to capture treatment-induced improvements in a fine-grained fashion [13][14][15] , thus suggesting a high potential as both progression and treatment response parameters in the upcoming treatment trials [16][17][18] . Recently, first studies showed that such measures of spatio-temporal variability characterizing ataxic gait can also be captured using wearable inertial sensors in clinical assessments 19,20 .…”

Targeting Expanded Repeats by Small Molecules in Repeat Expansion Disorders

“…Although much of the therapeutic research on diseases such as HD have attempted to discover ways for promoting the clearance of the abnormal proteins that cause neurodegeneration, none has yet been successful. Furthermore, while therapeutic development aimed at the degradation of abnormal mRNA using nucleic acid drugs—which have attracted attention in recent years—is progressing, and some technologies have advanced to the stage of clinical trials, 50 whether or not these drugs can be appropriately delivered to the central nervous system remains an open question. Amidst these events, the development of treatments that seek to modulate the length of abnormally expanded repeats—the more fundamental cause of repeat expansion disorders—has begun 51 .…”